Skip to main content

Table 2 Treatment Outcomes Among Osteosarcoma Patients Treated in Clinical Trial of Palliative Radiotherapy and Intra-tumoral Autologous NK Cells

From: Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial

Patient

Age (years)

Total NK Cells Injected (× 106)

Toxicity

Status

Survival Time (months)

Cause of Deatha

6-Month Metastasis-Free Survivalb

1

14.8

30.3

 

Dead

2.4

Metastases

No

2

9.1

25.34

Infection at injection site

Alive

8.1

n/a

Yes

3

9.1

547

 

Alive

11.2

n/a

Yesc

4

5.8

254.33

 

Alive

6.0

n/a

Yes

5

1.2

102.63

Grade 3 fever/chills/dehydration attributed to rhIL-2 reaction; Infection at injection site requiring surgery

Dead

8.1

Metastases

Yes

6

6.3

216.4

Infection at injection site requiring surgery

Dead

4.1

Perforated ulcer

No

7

7.5

234

 

Dead

2.9

Pathologic fracture/ metastases

No

8

5.0

305

 

Dead

1.6

Pathologic fracture

No

9

8.9

355

 

Alive

7.6

n/a

Yes

10

10.2

132

 

Dead

5.0

Metastases

No

  1. aAnimals were euthanized at owner’s request following diagnosis of index event
  2. bFreedom from pulmonary metastasis 6 months after enrollment was the primary endpoint of the clinical trial
  3. cPatient demonstrated resolution of suspicious pulmonary nodule post-radioimmunotherapy